AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03630796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
Study NCT03630796 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TIVA
Description: Total intravenous anesthesia
Study NCT05039749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Human Centric Lights
Description: Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
Study NCT04279886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Three-dimensional scans
Description: All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)
Study NCT03820544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangiopancreatography
Description: Undergo ERCP with SEMS placement
Study NCT03820544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Undergo standard of care surgical resection
Study NCT03771755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
Study NCT03771755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
Study NCT01386164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
Study NCT01386164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
Study NCT03678272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HERNIOPLASTY WITH PANAVALE MESH
Description: Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
Study NCT03678272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HERNIOPLASTY WITH PARIETEX PROGRIP MESH
Description: Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis.
Study NCT03678272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HERNIOPLASTY WITH ADHESIX MESH
Description: It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
Study NCT03678272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HERNIOPLASTY WITH TIMESH MESH
Description: Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
Study NCT00531765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate infusion
Description: short infusion of sodium bicarbonate
Study NCT00531765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate infusion
Description: short infusion of sodium bicarbonate
Study NCT01539759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate Postplacental Placement of an IUD during cesarean delivery
Description: Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
Study NCT01862146 — intervention group
Intervention type: PROCEDURE
Intervention: smoke expose
Study NCT00871767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 40 mg tablet (Test formulation)
Study NCT00871767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 40 mg tablet (Reference formulation)
Study NCT00871767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 100 mg tablet (Test formulation)
Study NCT00871767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 100 mg (2 x 50 mg tablet (Reference Formulation)
Study NCT04508946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c - thiamine- hydrocortisone
Description: Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
Study NCT04508946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin c - thiamine- hydrocortisone
Description: Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
Study NCT01335776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
Study NCT01335776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
Study NCT05195307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Group
Description: Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
Study NCT01746303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
Study NCT01746303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
Study NCT01746303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo oil
Description: Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
Study NCT01746303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
Study NCT01746303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
Study NCT01746303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
Study NCT03090477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and adherence aids
Description: Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
Study NCT03762408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENKO 1
Description: 50 mg of HA/ 50 mg of CS in 5 ml
Study NCT03762408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane
Description: 60 mg HA crosslinked in 3 ml
Study NCT00528112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCS12
Description: Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
Study NCT00528112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCS16
Description: Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
Study NCT04097431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response Blocking
Description: Physically preventing the response (i.e., precursor) from occurring.
Study NCT04326920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Description: Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
Study NCT04326920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sargramostim
Description: Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
Study NCT04326920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of care
Study NCT02313220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral use
Study NCT02313220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
Study NCT02313220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral and Subcutaneous use.
Study NCT03561675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study NCT03561675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study NCT00956163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo whole-body MRI
Study NCT00956163 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 sodium fluoride
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan
Study NCT00956163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan
Study NCT00956163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan
Study NCT00956163 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc 99m methylene diphosphonate
Description: Undergo technetium Tc 99m methylene diphosphonate bone scan
Study NCT04326166 — intervention group
Intervention type: DRUG
Intervention: Metformin and Evogliptin
Description: Metformin and Evogliptin
Study NCT01081054 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ambulatory versus hospitalisation
Description: Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
Study NCT01081054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory versus hospitalisation
Description: Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
Study NCT00956163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04132531 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric (weight loss) surgery
Description: Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
Study NCT01415362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit.
Study NCT02134756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NutraStem Active
Study NCT02134756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NutraStem Placebo
Study NCT00889590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
Study NCT02976298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: comparison of different conditions of transcranial magnetic stimulation
Study NCT02970799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Neurostimulator
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
Study NCT02900794 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gold Laser
Description: Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
Study NCT02900794 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdebridement
Description: Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
Study NCT02693808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous fat injection
Description: Injection in one side with autologous fat and the other side with hyaluronic acid.
Study NCT02693808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Injection in one side with autologous fat and the other side with hyaluronic acid.
Study NCT00461006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: 45mg po daily
Study NCT01415362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit.
Study NCT03206762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Description: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Study NCT00461006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 0.6mg po daily
Study NCT03009786 — intervention group
Intervention type: OTHER
Intervention: Measurement of salivary flow
Description: A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
Study NCT03759834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear promontory stimulation
Description: Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
Study NCT03249636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
Study NCT04068402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivio System
Description: The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
Study NCT03290846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin Human
Description: Randomized, single-blinded secretin hydrochloride infusion.
Study NCT03290846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Randomized, single-blinded saline infusion.
Study NCT03290846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: All subjects will undergo a cold exposure PET scan.
Study NCT01944137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Intervention
Description: Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
Study NCT00786669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
Study NCT00786669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
Study NCT00786669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
Study NCT00786669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
Study NCT00786669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
Study NCT04540263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
Study NCT02764463 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fiber Reinforced Composite Fixed Partial Dentures
Description: All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
Study NCT03179566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Sheet
Description: Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
Study NCT03179566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deterra Drug Deactivation System
Description: This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
Study NCT02600481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-pressure pneumoperitoneum
Description: Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
Study NCT02600481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard-pressure pneumoperitoneum
Description: Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.